This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xie, Z. Articles by Glazer, R. I. Search for Related Content PubMed PubMed Citation Articles by Xie, Z. Articles by Glazer, R. I.

Transformation of Mammary Epithelial Cells by 3-Phosphoinositide- dependent Protein Kinase-1 Activates ß-Catenin and c-Myc, and Down-Regulates Caveolin-1¹

Department of Oncology and Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20057

3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a pivotal role in coupling growth factor receptor signaling to tumor cell proliferation, survival, and invasion. Protein kinase C (PKC) , but not Akt1, was found previously to be downstream of PDK1-mediated transformation of mammary epithelial cells. To determine the basis for its oncogenic activity, signal transduction pathways mediated by PDK1 in mammary epithelial cells were investigated. ß-Catenin/T-cell factor-dependent promoter activity was markedly activated in PDK1- and PKC-expressing cells, but not in Akt1-expressing cells, which resulted in increased levels of the ß-catenin/T-cell factor target genes c-myc and cyclin D1. In contrast, caveolin-1, of which the transcription is suppressed by c-myc, was down-regulated in PDK1- and PKC-expressing, but not in Akt1-expressing cells. Analysis of 16 breast cancer cell lines established that caveolin-1 expression was either absent or reduced compared with breast epithelial cells, and that PDK1 was elevated in all of the cell lines. Interestingly, all of the cell lines known to be invasive expressed caveolin-1 to some degree, whereas, 5 of 6 cell lines that are not invasive did not express caveolin-1. Therefore, it appears that a concomitant gain of c-myc function and a loss or reduction of caveolin-1 are major determinants of PDK1- and PKC-mediated mammary oncogenesis.

This article has been cited by other articles:

				L. C. Matthews, M. J. Taggart, and M. Westwood Modulation of Caveolin-1 Expression Can Affect Signalling through the Phosphatidylinositol 3-Kinase/Akt Pathway and Cellular Proliferation in Response to Insulin-Like Growth Factor I Endocrinology, October 1, 2008; 149(10): 5199 - 5208. [Abstract] [Full Text] [PDF]

				A. N. Shajahan, A. Wang, M. Decker, R. D. Minshall, M. C. Liu, and R. Clarke Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity J. Biol. Chem., February 23, 2007; 282(8): 5934 - 5943. [Abstract] [Full Text] [PDF]

				K. Liang, Y. Lu, X. Li, X. Zeng, R. I. Glazer, G. B. Mills, and Z. Fan Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine Mol. Pharmacol., September 1, 2006; 70(3): 1045 - 1052. [Abstract] [Full Text] [PDF]

				H. Tanaka, N. Fujita, and T. Tsuruo 3-Phosphoinositide-dependent Protein Kinase-1-mediated I{kappa}B Kinase {beta} (IKKB) Phosphorylation Activates NF-{kappa}B Signaling J. Biol. Chem., December 9, 2005; 280(49): 40965 - 40973. [Abstract] [Full Text] [PDF]

				Y. Yin, R. G. Russell, L. E. Dettin, R. Bai, Z.-L. Wei, A. P. Kozikowski, L. Kopleovich, and R. I. Glazer Peroxisome Proliferator-Activated Receptor {delta} and {gamma} Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis Cancer Res., May 1, 2005; 65(9): 3950 - 3957. [Abstract] [Full Text] [PDF]

				T. M. Williams and M. P. Lisanti Caveolin-1 in oncogenic transformation, cancer, and metastasis Am J Physiol Cell Physiol, March 1, 2005; 288(3): C494 - C506. [Abstract] [Full Text] [PDF]

				F. Maupas-Schwalm, C. Robinet, N. Auge, J.-C. Thiers, V. Garcia, J.-P. Cambus, R. Salvayre, and A. Negre-Salvayre Activation of the {beta}-Catenin/T-Cell-Specific Transcription Factor/Lymphoid Enhancer Factor-1 Pathway by Plasminogen Activators in ECV304 Carcinoma Cells Cancer Res., January 15, 2005; 65(2): 526 - 532. [Abstract] [Full Text] [PDF]